“I had treatment last year and I want to give something back.”
A study looking at eribulin for advanced breast cancer
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
Cancer type:
Breast cancer
Status:
Closed
Phase:
Phase 4
This study is to find out more about the chemotherapy drug eribulin as a treatment for breast cancer that has spread into the surrounding tissue (locally advanced) or to another part of the body (secondary breast cancer).
Doctors can treat locally advanced and secondary breast cancer with chemotherapy. One chemotherapy drug they use is eribulin. We know eribulin works, but not how well it works in practice.
In this study the researchers want to collect information about a group of people who are taking eribulin for their locally advanced or secondary breast cancer. This will include information about how you are doing, what other medications you are taking, any side effects and other treatments you may have.
The aims of this study are to find out
- How well eribulin works for people with locally advanced and secondary breast cancer
- How safe it is
Who can enter
You may be able to enter this trial if
- You are taking eribulin at the moment
- You have breast cancer that has spread to surrounding tissue (locally advanced) or has spread to another part of your body (secondary breast cancer)
- Your cancer came back after treatment with 1 or 2 different types of chemotherapy
- Your blood test results are satisfactory
- You are at least 18 years old
You cannot enter this trial if
- This isn’t the first time you have taken eribulin
- You have had treatment for locally advanced or secondary breast cancer with more than 2 different types of chemotherapy
Trial design
This is a phase 4 study. It will recruit 150 people. Everyone will have eribulin.
While you are on the study, your cancer doctor will collect information about how you are doing, what other medications you are taking, any side effects and other treatments you may have as long as you are taking eribulin.
You remain part of the study as long as you are taking eribulin.
Hospital visits
There are no extra visits to the hospital if you take part in this study.
Side effects
We have information about eribulin and its side effects in our cancer drugs section.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
Chief Investigator
Dr Hartmut Kristeleit
Supported by
Eisai
NIHR Clinical Research Network: Cancer
Questions about cancer? Contact our information nurses
Freephone 0808 800 4040
Last review date
CRUK internal database number:
Oracle 10960
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
Caroline took part in a clinical trial for breast cancer
Last reviewed:
About Cancer generously supported by
Dangoor Education since 2010.
Dangoor Education since 2010.